About Jubilant Therapeutics

Jubilant Therapeutics Inc., a subsidiary of Jubilant Life Sciences Ltd., is a U.S based innovative biopharmaceutical company developing breakthrough therapies for treating unmet medical need in serious diseases such as cancer.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and other businesses including Drug Discovery Solutions, India Branded Pharmaceuticals and Proprietary Innovation. For more info: www.jubl.com

Press Release

Jubilant Life Sciences Announces Appointment of Dr. Syed Kazmi as President and CEO of its New Innovative Biopharmaceutical Company in the U.S. – Jubilant Therapeutics Inc.

Yardley, PA, United States; Sep 09, 2019

Jubilant Life Sciences Limited has announced that Dr. Syed Kazmi, PhD, MBA, will join its new innovative biopharmaceutical company in the U.S., Jubilant Therapeutics Inc., as President and Chief Executive Officer.

Dr. Kazmi joins from Novartis Pharmaceuticals Corporation where he was Vice President, Global Head of Business Development & Licensing for Oncology.

Business Model and Strategy

Jubilant Therapeutics is a capital efficient, semi-virtual biopharma with agile business model and asset specific subsidiaries for creative partnerships. The company’s core strategy is to develop novel and targeted small molecule therapies primarily in the area of Oncology and Auto-Immune disorders.

Jubilant Therapeutics Plans

Jubilant Therapeutics plans to work on a portfolio of new chemical entities and fast track promising assets from discovery phase into development phase (Clinical POC) by leveraging key strengths:

  • Powerful Discovery engine using structure based design, computational modeling and bio informatics
  • Independent scientific and management team shaping the portfolio
  • Globally renowned KOLs and scientific advisory board advising on individual programs
  • Toxicology and Clinical experts to take lead programs to the clinic
  • Flexible partnering options within biopharma ecosystem including academia
  • Synergistic capabilities of Jubilant Life Sciences and its other subsidiaries in bio-pharma value chain
  • Collaboration on R&D and development activities with global CROs including Jubilant Biosys, which is a strategic partner


Lead Programs, Indication
Status Description
BRD4, Liquid and solid tumors, Epigenetics Pre-clinical Partnered with Checkpoint Therapeutics at lead stage with potential milestones of $180m. Successfully completed toxicology studies with expected progress to Phase I clinical trials near-term.
LSD1/HDAC6 –Dual Inhibitor, MDS/AML, Epigenetics Pre-clinical Novel dual first in class epigenetic inhibitors of LSD1/HDAC6 to address unmet needs in liquid cancers like acute myeloid leukemia (AML).
PDL-1, Broad spectrum of Cancer, Immuno-Oncology Lead optimisation Small molecule therapy with comparable efficacy to large molecules with lower side effects.Complete lead optimisation near-term.
PAD4, Inflammation and auto immune disorder, Epigenetics Lead optimisation Potential to address unmet needs in multiple auto-immune disorders like rheumatoid arthritis, psoriasis etc. Preclinical candidate nomination near-term.
PRMT5, Lymphoma, Epigenetics Lead identification Complete lead identification near-term.

Get In Touch

U.S Office

790 Township Line Road, Suite 175 Yardley, PA 19067, USA
Tel: +1 215 550 2810

India Office

#96, Industrial Suburb 2nd Stage, Yeshwantpur Bengaluru - 560 022 Karnataka India.
Tel. : +91 80 66628400, 66628250